Analyst Price Target is $8.33
▲ +76.18% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Codexis in the last 3 months. The average price target is $8.33, with a high forecast of $11.00 and a low forecast of $5.00. The average price target represents a 76.18% upside from the last price of $4.73.
Current Consensus is
Moderate Buy
The current consensus among 3 polled investment analysts is to moderate buy stock in Codexis. This rating has held steady since August 2024, when it changed from a Buy consensus rating.
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Read More